Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities
The DOI matches its Crossref record.
Abstract
Glucose-6-phosphate dehyrdgoenase (G6PD) deficiency is a common X-linked genetic trait, with an associated enzyme phenotype, whereby males are either G6PD deficient or normal, but females exhibit a broader range of G6PD deficiencies, ranging from severe deficiency to normal. Heterozygous females typically have intermediate G6PD activity. G6PD deficiency has implications for the safe treatment for Plasmodium vivax malaria. Individuals with this deficiency are at greater risk of serious adverse events following treatment with the only curative class of anti-malarials, 8-aminoquinolines, such as primaquine. Quantitative diagnostic tests for G6PD deficiency are complex and require sophisticated laboratories. The commonly used qualitative tests, do not discriminate intermediate G6PD activities. This has resulted in poor understanding of the epidemiology of G6PD activity in females and its corresponding treatment ramifications. New simple-to-use quantitative tests, and a momentum to eliminate malaria, create an opportunity to address this knowledge gap. While this will require additional resources for clinical studies, adequate operational research, and appropriate pharmacovigilance, the health benefits from this investment go beyond the immediate intervention for which the G6PD status is first diagnosed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The result of our study is in agreement with a previous research article [34], which states that females are more affected by G6PDd.”
From Pooled prevalence of Glucose-6-phosphate dehydrogenase deficiency among malaria patients in Ethiopia: a systematic review and meta-analysis (2026) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 45
- Cappellini, 2008, Glucose-6-phosphate dehydrogenase deficiency, Lancet, 371, 64, 10.1016/S0140-6736(08)60073-2 · DOI · Paper page
- Luzzatto, 2016, Glucose-6-phosphate dehydrogenase deficiency, Hematol Oncol Clin North Am, 30, 373, 10.1016/j.hoc.2015.11.006 · DOI · Paper page
- Nkhoma, 2009, The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis, Blood Cells Mol Dis, 42, 267, 10.1016/j.bcmd.2008.12.005 · DOI · Paper page
- Gomez-Manzo, 2016, Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world, Int J Mol Sci, 17, 10.3390/ijms17122069 · DOI · Paper page
- Beutler, 1994, G6PD deficiency, Blood, 84, 3613, 10.1182/blood.V84.11.3613.bloodjournal84113613 · DOI · Paper page
- Beutler, 1962, The normal human female as a mosaic of X-chromosome activity: studies using the gene for C-6-PD-deficiency as a marker, Proc Natl Acad Sci USA, 48, 9, 10.1073/pnas.48.1.9 · DOI · Paper page
- Bancone, 2017, The G6PD flow-cytometric assay is a reliable tool for diagnosis of G6PD deficiency in women and anaemic subjects, Sci Rep, 7, 9822, 10.1038/s41598-017-10045-2 · DOI
- LaRue, 2014, Comparison of quantitative and qualitative tests for glucose-6-phosphate dehydrogenase deficiency, Am J Trop Med Hyg, 91, 854, 10.4269/ajtmh.14-0194 · DOI · Paper page
- Nantakomol, 2013, Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency, Malar J, 12, 289, 10.1186/1475-2875-12-289 · doi:10.1186/1475-2875-12-289
- Peters, 2017, Comparison of spectrophotometry, chromate inhibition, and cytofluorometry versus gene sequencing for detection of heterozygously glucose-6-phosphate dehydrogenase-deficient females, J Histochem Cytochem, 65, 627, 10.1369/0022155417730021 · DOI
- Kalnoky, 2017, Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression, Eur J Haematol, 100, 294, 10.1111/ejh.13013 · DOI
- Cunningham, 2016, Glucose-6-phosphate dehydrogenase deficiency and the need for a novel treatment to prevent kernicterus, Clin Perinatol, 43, 341, 10.1016/j.clp.2016.01.010 · DOI
- Kaplan, 2010, Glucose-6-phosphate dehydrogenase deficiency and severe neonatal hyperbilirubinemia: a complexity of interactions between genes and environment, Semin Fetal Neonatal Med, 15, 148, 10.1016/j.siny.2009.10.007 · DOI
- Olusanya, 2014, Addressing the burden of neonatal hyperbilirubinaemia in countries with significant glucose-6-phosphate dehydrogenase deficiency, Acta Paediatr, 103, 1102, 10.1111/apa.12735 · DOI
- 1989, Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group, Bull World Health Organ, 67, 601
- Domingo, 2013, G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests, Malar J, 12, 391, 10.1186/1475-2875-12-391 · DOI · Paper page
- Reclos, 2000, Glucose-6-phosphate dehydrogenase deficiency neonatal screening: preliminary evidence that a high percentage of partially deficient female neonates are missed during routine screening, J Med Screen, 7, 46, 10.1136/jms.7.1.46 · doi:10.1136/jms.7.1.46
- Van Noorden, 1989, Flow cytofluorometric analysis of enzyme reactions based on quenching of fluorescence by the final reaction product: detection of glucose-6-phosphate dehydrogenase deficiency in human erythrocytes, J Histochem Cytochem, 37, 1313, 10.1177/37.9.2768805 · doi:10.1177/37.9.2768805
- Kalnoky, 2018, Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression, Eur J Haematol, 100, 294, 10.1111/ejh.13013 · DOI
- Crow, 1999, Hardy, Weinberg and language impediments, Genetics, 152, 821, 10.1093/genetics/152.3.821 · DOI
- Howes, 2012, G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map, PLoS Med, 9, e1001339, 10.1371/journal.pmed.1001339 · DOI · Paper page
- Clarke, 2017, Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia, Elife, 6, 15085, 10.7554/eLife.15085 · DOI
- Kwiatkowski, 2005, How malaria has affected the human genome and what human genetics can teach us about malaria, Am J Hum Genet, 77, 171, 10.1086/432519 · DOI · Paper page
- Ruwende, 1995, Natural selection of hemi- and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria, Nature, 376, 246, 10.1038/376246a0 · DOI · Paper page
- Baird, 2015, Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria, Pathog Glob Health, 109, 93, 10.1179/2047773215Y.0000000016 · DOI
- Luzzatto, 2010, The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics, Lancet, 376, 739, 10.1016/S0140-6736(10)60396-0 · DOI
- Douglas, 2013, Major burden of severe anemia from non-falciparum malaria species in Southern Papua: a hospital-based surveillance study, PLoS Med, 10, e1001575, 10.1371/journal.pmed.1001575 · DOI · Paper page
- Kenangalem, 2016, Plasmodium vivax infection: a major determinant of severe anaemia in infancy, Malar J, 15, 321, 10.1186/s12936-016-1373-8 · DOI
- Luxemburger, 1999, Treatment of vivax malaria on the western border of Thailand, Trans R Soc Trop Med Hyg, 93, 433, 10.1016/S0035-9203(99)90149-9 · DOI
- Robinson, 2015, Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model, PLoS Med, 12, e1001891, 10.1371/journal.pmed.1001891 · DOI · Paper page
- Llanos-Cuentas, 2014, Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study, Lancet, 383, 1049, 10.1016/S0140-6736(13)62568-4 · DOI · Paper page
- Lubell, 2014, Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations, PLoS Med, 11, e1001704, 10.1371/journal.pmed.1001704 · DOI
- 2016, Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of eighth biannual meeting (September 2015), Malar J, 15, 117, 10.1186/s12936-016-1169-x · DOI · Paper page
- Chu, 2017, Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens, PLoS Med, 14, e1002224, 10.1371/journal.pmed.1002224 · DOI · Paper page
- Rueangweerayut, 2017, Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD mahidol variant) versus G6PD-normal volunteers, Am J Trop Med Hyg, 97, 702, 10.4269/ajtmh.16-0779 · DOI · Paper page
- Chu, 2018, Primaquine-induced haemolysis in females heterozygous for G6PD deficiency, Malar J, 17, 101, 10.1186/s12936-018-2248-y · DOI · Paper page
- Wang, 2009, Comparison of detection of glucose-6-phosphate dehydrogenase deficiency using fluorescent spot test, enzyme assay and molecular method for prediction of severe neonatal hyperbilirubinaemia, Singapore Med J, 50, 62
- Kaplan, 1999, Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes, Pediatrics, 104, 68, 10.1542/peds.104.1.68 · doi:10.1542/peds.104.1.68
- Kaplan, 2001, Acute hemolysis and severe neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes, J Pediatr, 139, 137, 10.1067/mpd.2001.115312 · DOI
- Meloni, 1983, Neonatal hyperbilirubinaemia in heterozygous glucose-6-phosphate dehydrogenase deficient females, Br J Haematol, 53, 241, 10.1111/j.1365-2141.1983.tb02017.x · DOI
- Riskin, 2012, Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia, J Pediatr, 161, 191, 10.1016/j.jpeds.2012.02.018 · doi:10.1016/j.jpeds.2012.02.018
- Fu, 2018, Newborn screening of glucose-6-phosphate dehydrogenase deficiency in Guangxi, China: determination of optimal cutoff value to identify heterozygous female neonates, Sci Rep, 8, 833, 10.1038/s41598-017-17667-6 · DOI
- Kitchakarn, 2017, Implementation of G6PD testing and primaquine for P. vivax radical cure: operational perspectives from Thailand and Cambodia, WHO South East Asia J Publ Health, 6, 60, 10.4103/2224-3151.213793 · DOI
- Ong, 2017, Systematic review of the clinical manifestations of glucose-6-phosphate dehydrogenase deficiency in the Greater Mekong Subregion: implications for malaria elimination and beyond, BMJ Glob Health, 2, e000415, 10.1136/bmjgh-2017-000415 · DOI
- Bancone, 2015, Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests, Am J Trop Med Hyg, 92, 818, 10.4269/ajtmh.14-0696 · DOI · Paper page
Cited by
Dessie, G., Getnet, M., Getahun, A. B., Mengstie, T. A., Asefa, T., Enyew, E. F., Yewodiaw, T. K., Endale, H. T., & Endalew, H. L. (2026) · Malaria Journal · doi:10.1186/s12936-026-05800-8
Metadata
- Authors
- Domingo, G. J., Advani, N., Satyagraha, A. W., Sibley, C. H., Rowley, E., Kalnoky, M., Cohen, J., Parker, M., & Kelley, M.
- Venue
- International Health
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-09-03
- Volume
- 11
- Issue
- 1
- Pages
- 7-14
- ISSN
- 1876-3413
- 1876-3405
- Cited by
- 67
- References
- 0
- Language
- en
- Funders
- UK Department for International Development (204139)
- Bill & Melinda Gates Foundation (OPP1107113)
- Wellcome Trust (096527)
- Wellcome Trust and MRC Newton Fund Collaborative (200344)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. https://app.cochat.ai/papers/10.1093/inthealth/ihy060
- The paper
- Domingo, G. J., Advani, N., Satyagraha, A. W., Sibley, C. H., Rowley, E., Kalnoky, M., Cohen, J., Parker, M., & Kelley, M. (2019). Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. International Health. https://doi.org/10.1093/inthealth/ihy060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.